The use of immune checkpoint inhibitors (ICIs) targeting programmed cell death protein 1 (PD1) and its ligand PDL1, have dramatically improved the treatment landscape for non-small cell lung cancer (NSCLC) patients. The gene discussed is CD274; the disease is non-small cell lung carcinoma.